References
- Zwaan C M, Kaspers G J. Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. Br J Haematol 2004; 127: 264–279
- Savaşan S, Buck S, Raimondi S C, Becton D L, Weinstein H, Chang M. CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: In vitro drug sensitivity and outcome. Leuk Lymphoma 2006; 47: 2076–2083
- Gurbuxani S, Vyas P, Crispino J D. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 2004; 103: 399–406
- Athale U H, Razzouk B I, Raimondi S C, Tong X, Behm F G, Head D R, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood 2001; 97: 3727–3732
- Ge Y, Stout M L, Tatman D A, Jensen T L, Buck S, Thomas R L, et al. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst 2005; 97: 226–231
- Bourquin J P, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci USA 2006; 103: 3339–3344